12 results on '"Anne Vachée"'
Search Results
2. Performance and Impact on Antibiotic Prescriptions of a Multiplex PCR in a Real-Life Cohort of Critically Ill Patients with Suspected Ventilated Pneumonia: A Retrospective Monocentric Observational Study
- Author
-
Emma Chambe, Perrine Bortolotti, Rémy Diesnis, Caroline Laurans, Rozenn Héquette-Ruz, Sophie Panaget, Patrick Herbecq, Anne Vachée, and Agnès Meybeck
- Subjects
pneumonia ,multiplex PCR ,COVID-19 ,antibiotic use ,intensive care ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Pulmonary multiplex polymerase chain reaction (m-PCR) allows rapid pathogen detection. We aimed to assess its impact on initial antibiotic prescriptions in ventilated patients with suspected pneumonia. Between November 2020 and March 2022,ventilated patients with suspected pneumonia hospitalized in our ICU who benefited from respiratory sampling simultaneously tested using conventional microbiological methods and m-PCR were included. The proportion of appropriate changes in the initial antibiotic therapy following m-PCR results was assessed. We analyzed 104 clinical samples. Of the 47 negative m-PCR results, 16 (34%) led to an appropriate antibiotic strategy: 8 cessationsand 8 lack of initiation. Of the 57 positive m-PCR results, 51 (89%) resulted in an appropriate antibiotic strategy: 33 initiations, 2 optimizations, and 9 de-escalations. In the multivariate analysis, a positive m-PCR was associated with an appropriate antibiotic change (OR: 96.60; IC95% [9.72; 960.20], p < 0.001). A higher SAPS II score was negatively associated with an appropriate antibiotic change (OR: 0.96; IC95% [0.931; 0.997], p = 0.034). In our cohort, a positive m-PCR allowed for early initiation or adjustment of antibiotic therapy in almost 90% of cases. A negative m-PCR spared antibiotic use in onethird of cases. The impact of m-PCR results was reduced in the most severe patients. more...
- Published
- 2023
- Full Text
- View/download PDF
Catalog
3. Antibiotic Prescriptions in Critically Ill Patients with Bloodstream Infection Due to ESBL-Producing Enterobacteriaceae: Compliance with the French Guidelines for the Treatment of Infections with Third-Generation Cephalosporin-Resistant Enterobacteriaceae—A Multicentric Retrospective Cohort Study
- Author
-
Camille Le Berre, Marion Houard, Anne Vachée, Hugues Georges, Frederic Wallet, Pierre Patoz, Patrick Herbecq, Saad Nseir, Pierre-Yves Delannoy, and Agnès Meybeck
- Subjects
extended-spectrum beta-lactamase-producing Enterobacteriaceae ,carbapenem sparing ,guidelines ,antibiotics ,critical care ,bacteremia ,Biology (General) ,QH301-705.5 - Abstract
National and international guidelines were recently published regarding the treatment of Enterobacteriaceae resistant to third-generation cephalosporins infections. We aimed to assess the implementation of the French guidelines in critically ill patients suffering from extended-spectrum β-lactamase-producing Enterobacteriaceae bloodstream infection (ESBL-E BSI). We conducted a retrospective observational cohort study in the ICU of three French hospitals. Patients treated between 2018 and 2022 for ESBL-E BSI were included. The primary assessment criterion was the proportion of adequate empirical carbapenem prescriptions, defined as prescriptions consistent with the French guidelines. Among the 185 included patients, 175 received an empirical anti-biotherapy within 24 h of ESBL-E BSI onset, with a carbapenem for 100 of them. The proportion of carbapenem prescriptions consistent with the guidelines was 81%. Inconsistent prescriptions were due to a lack of prescriptions of a carbapenem, while it was recommended in 25% of cases. The only factor independently associated with adequate empirical carbapenem prescription was ESBL-E colonization (OR: 107.921 [9.303–1251.910], p = 0.0002). The initial empirical anti-biotherapy was found to be appropriate in 83/98 patients (85%) receiving anti-biotherapy in line with the guidelines and in 56/77 (73%) patients receiving inadequate anti-biotherapy (p = 0.06). Our results illustrate the willingness of intensivists to spare carbapenems. Promoting implementation of the guidelines could improve the proportion of initial appropriate anti-biotherapy in critically ill patients with ESBL-E BSI. more...
- Published
- 2023
- Full Text
- View/download PDF
4. Management of patients with pulmonary mycobacteriosis in France: a multicenter retrospective cohort study
- Author
-
Pascale Bemer, Olivia Peuchant, Hélène Guet-Revillet, Julien Bador, Charlotte Balavoine, Damien Basille, Guillaume Beltramo, François-Xavier Blanc, Elodie Blanchard, Sarah Boulanger, Anne Bourgoin, David Boutoille, Emmanuelle Cambau, Frédérique Canis, Didier Caparros, Anne Carricajo, Christian Carrière, Gérard Couetdic, Francis Couturaud, Jean-Charles Dalphin, Tristan Degot, Marion Desquiens, Gilles Devouassoux, Jean-Marie Duez, Oana Dumitrescu, Magali Dupuy-Grasset, Alice Gaudart, Marjolaine Georges, Cendrine Godet, Sylvain Godreuil, Aurélie Guillouzouic, Farida Hamdad-Daoudi, Geneviève Héry-Arnaud, Christelle Koebel, Aurore Lagrange, Philippe Lanotte, Sylvain Marchand-Adam, Faïza Mougari, Marlène Murris, Isabelle Patry, Michèle Pérouse de Montclos, Laurent Raskine, Karine Risso, Christine Segonds, Dominique Sicard, Dominique Terru, Anne Vachée, Jean-Michel Vergnon, Christian Martin, Frédéric Schramm, and Claire Andrejak more...
- Subjects
Nontuberculous mycobacteria ,Mycobacterium xenopi ,Mycobacterium avium complex ,Prognosis ,Management ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background Recent studies report very low adherence of practitioners to ATS/IDSA recommendations for the treatment of nontuberculous mycobacteria pulmonary disease (NTM-PD), as well as a great variability of practices. Type of management could impact prognosis. Methods To evaluate management and prognosis of patients with NTM-PD cases with respect to ATS recommendations, we conducted a multicenter retrospective cohort study (18 sentinel sites distributed throughout France), over a period of six years. We collected clinical, radiological, microbiological characteristics, management and outcome of the patients (especially death or not). Results 477 patients with NTM-PD were included. Respiratory comorbidities were found in 68% of cases, tuberculosis sequelae in 31.4% of patients, and immunosuppression in 16.8% of cases. The three most common NTM species were Mycobacterium avium complex (60%), M. xenopi (20%) and M. kansasii (5.7%). Smear-positive was found in one third of NTM-PD. Nodulobronchiectatic forms were observed in 54.3% of cases, and cavitary forms in 19.1% of patients. Sixty-three percent of patients were treated, 72.4% of patients with smear-positive samples, and 57.5% of patients with smear-negative samples. Treatment was in adequacy with ATS guidelines in 73.5%. The 2-year mortality was 14.4%. In the Cox regression, treatment (HR = 0.51), age (HR = 1.02), and M. abscessus (3.19) appeared as the 3 significant independent prognostic factors. Conclusion These findings highlight the adequacy between French practices and the ATS/IDSA guidelines. Treatment was associated with a better survival. more...
- Published
- 2021
- Full Text
- View/download PDF
5. Prospective Whole-Genome Sequencing in Tuberculosis Outbreak Investigation, France, 2017–2018
- Author
-
Charlotte Genestet, Caroline Tatai, Jean-Luc Berland, Jean-Baptiste Claude, Emilie Westeel, Elisabeth Hodille, Isabelle Fredenucci, Jean-Philippe Rasigade, Michael Ponsoda, Véronique Jacomo, Anne Vachée, Alice Gaudart, Jean-Louis Gaillard, Anne-Laure Roux, Florence Ader, Karim Tararbit, Garance Terpant, Juliet E. Bryant, Gérard Lina, and Oana Dumitrescu more...
- Subjects
Tuberculosis ,Mycobacterium tuberculosis ,epidemiologic monitoring ,disease outbreaks ,whole-genome sequencing ,drug susceptibility ,Medicine ,Infectious and parasitic diseases ,RC109-216 - Abstract
During June 2017–April 2018, active tuberculosis with Beijing SIT1 isolates was diagnosed in 14 persons living in 4 distant cities in France. Whole-genome sequencing indicated that these patients belonged to a single transmission chain. Whole-genome sequencing–based laboratory investigations enabled prompt tracing of linked cases to improve tuberculosis control. more...
- Published
- 2019
- Full Text
- View/download PDF
6. A prospective, observational study of fidaxomicin use for infection in France
- Author
-
Benoit Guery, Pierre Berger, Remy Gauzit, Magali Gourdon, Frédéric Barbut, DAFNE study group:, Pascale Bémer, Emilie Bessède, Fabrice Camou, Vincent Cattoir, Carine Couzigou, Dominique Descamps, Aurélien Dinh, Caroline Laurans, Jean-Philippe Lavigne, Catherine Lechiche, Véronique Leflon-Guibout, Alban Le Monnier, Marion Levast, Joy Yoganaden Mootien, Yohan N’Guyen, Lionel Piroth, Thierry Prazuck, Olivier Rogeaux, Anne-Laure Roux, Anne Vachée, Véronique Vernet Garnier, and Frédéric Wallet more...
- Subjects
Medicine (General) ,R5-920 - Abstract
Objective To describe the characteristics, management and outcomes of hospitalised patients with Clostridioides difficile infection (CDI) treated with and without fidaxomicin. Methods This prospective, multicentre, observational study (DAFNE) enrolled hospitalised patients with CDI, including 294 patients treated with fidaxomicin (outcomes recorded over a 3-month period) and 150 patients treated with other CDI therapies during three 1-month periods. The primary endpoint was baseline and CDI characteristics of fidaxomicin-treated patients. Results At baseline, the fidaxomicin-treated population included immunocompromised patients (39.1%) and patients with severe (59.2%) and recurrent (36.4%) CDI. Fidaxomicin was associated with a high rate of clinical cure (92.2%) and low CDI recurrence (16.3% within 3 months). Clinical cure rates were ≥90% in patients aged ≥65 years, those receiving concomitant antibiotics and those with prior or severe CDI. There were 121/296 (40.9%) patients with adverse events (AEs), 5.4% with fidaxomicin-related AEs and 1.0% with serious fidaxomicin-related AEs. No fidaxomicin-related deaths were reported. Conclusions Fidaxomicin is an effective and well-tolerated CDI treatment in a real-world setting in France, which included patients at high risk of adverse outcomes. Trial registration: Description of the use of fidaxomicin in hospitalised patients with documented Clostridium difficile infection and the management of these patients (DAFNE), NCT02214771, www.ClinicalTrials.gov. more...
- Published
- 2021
- Full Text
- View/download PDF
7. Combination Therapy with Aminoglycoside in Bacteremiasdue to ESBL-Producing Enterobacteriaceae in ICU
- Author
-
Lucie Benetazzo, Pierre-Yves Delannoy, Marion Houard, Frederic Wallet, Fabien Lambiotte, Anne Vachée, Christian Batt, Nicolas Van Grunderbeeck, Saad Nseir, Olivier Robineau, and Agnès Meybeck
- Subjects
antimicrobialcombination ,efficacy of combinations ,aminoglycoside ,bloodstream infections ,extended-spectrum β-lactamase producing Enterobacteriaceae ,critical care ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Objectives: Evaluation of the efficacy of empirical aminoglycoside in critically ill patients with bloodstream infections caused by extended-spectrum β-lactamase producing Enterobacteriaceae (ESBL-E BSI). Methods: Patients treated between 2011 and 2018 for ESBL-E BSI in the ICU of six French hospitals were included in a retrospective observational cohort study. The primary endpoint was mortality on day 30. Results: Among 307 patients, 169 (55%) were treated with empirical aminoglycoside. Death rate was 40% (43% with vs. 39% without aminoglycoside, p = 0.55). Factors independently associated with death were age ≥70 years (OR: 2.67; 95% CI: 1.09–6.54, p = 0.03), history of transplantation (OR 5.2; 95% CI: 1.4–19.35, p = 0.01), hospital acquired infection (OR 8.67; 95% CI: 1.74–43.08, p = 0.008), vasoactive drugs >48 h after BSI onset (OR 3.61; 95% CI: 1.62–8.02, p = 0.001), occurrence of acute respiratory distress syndrome (OR 2.42; 95% CI: 1.14–5.16, p = 0.02), or acute renal failure (OR 2.49; 95% CI: 1.14–5.47, p = 0.02). Antibiotherapy appropriateness was more frequent in the aminoglycoside group (91.7% vs. 77%, p = 0.001). Rate of renal impairment was similar in both groups (21% vs. 24%, p = 0.59). Conclusions: In intensive care unit (ICU) patients with ESBL-E BSI, empirical treatment with aminoglycoside was frequent. It demonstrated no impact on mortality, despite increasing treatment appropriateness. more...
- Published
- 2020
- Full Text
- View/download PDF
8. Familial Transmission of emm12 Group A Streptococcus
- Author
-
Claire Duployez, Anne Vachée, Olivier Robineau, François Giraud, Anthony Deny, Eric Senneville, Frédéric Wallet, and Caroline Loïez
- Subjects
Streptococcus pyogenes ,group A streptococcal infections ,iGAS ,emm12 ,familial ,invasive ,Medicine ,Infectious and parasitic diseases ,RC109-216 - Abstract
Incidence and severity of invasive group A Streptococcus infections are of increasing concern in France and worldwide. The risk for secondary infection of close contacts is known but rarely described. We report a case of intrafamilial and life-threatening transmission of emm12 group A Streptococcus. more...
- Published
- 2017
- Full Text
- View/download PDF
9. Effects of azithromycin and doxycycline on the vaginal microbiota of women with urogenital Chlamydia trachomatis infection: a substudy of the Chlazidoxy randomized controlled trial
- Author
-
Jeanne Tamarelle, Benjamin Penaud, Benjamin Tyssandier, Erwan Guichoux, Bertille de Barbeyrac, Olivia Peuchant, Dounia Baita, Catherine Ouziel-Duretz, Béatrice Poudens, Raquel Brun, Sophie Jouvert, Aurore Tesson, Jennifer Carrière, Marie Diaz, Camille Forget, Isabelle Le Hen, France Ahano-Ducourneau, Delphine Ha Van, Pauline Robert, Fabienne Brun, Estelle Lhospital, Julie Bardou, Annaïg Guegan, Sandy Ramloll Moura, Céline Leriche, Alix De Cussy, Marlène Malfait, Charlotte Rychen, Pervenche Martinet, Audrey Kugeler, Lisa Barriere, Laura Gutierrez, Jean-Luc Robert, Julie Saule, Viviana Bergamaschi, Sana Ben Soltana, Dominique Aymar-Moulene, Claire Bernier, Anne-Sophie Lecompte, Antoine Gregoire, Thomas Girard, Marie-Astrid Naccache, Philippe Lefebvre, Pauline Crombe, Christine Bulot, Anne-Laure Rolland, Katy Dernivoix, Camille Trouillet, Nathalie Trignol-Viguier, Elisabeth Blin-Zbiegiel, Mélanie Boissinot, Bruno Joly, Anne Dubreuil, Camille Mathieu, David Pragout, Cécile Bébéar, Anne Grob, Sophie Zaffreya, Erwan Le Naour, Anne Sophie Gibaud, Philippe Lanotte, Anne Vachée, Julien Loubinoux, Arabella Touati, Carla Balcon, Caroline Roussillon, Bellabes Ghezzoul, Frédéric Perry, Christelle Turuban, Sabine Rapin, Christine Pastor, Morane Cavellec, Ernesto Paredes Manvri, Sonia Albane, Eva Ghiringhelli, Karen Pantin, Marion Kret, Edouard Lhomme, Damien Garreau, and Jérôme Galet more...
- Subjects
Microbiology (medical) ,Infectious Diseases ,General Medicine - Published
- 2023
- Full Text
- View/download PDF
10. Identification of a New DNA Region Specific for Members of Mycobacterium tuberculosis Complex
- Author
-
Camille Locht, Anne Vachée, Philip Supply, and Juana Magdalena
- Subjects
DNA, Bacterial ,Microbiology (medical) ,Mycobacterium bovis ,biology ,Mycobacteriology and Aerobic Actinomycetes ,Mycobacterium tuberculosis ,Spacer DNA ,biology.organism_classification ,Polymerase Chain Reaction ,Sensitivity and Specificity ,Virology ,Microbiology ,Intergenic region ,Mycobacterium tuberculosis complex ,Mycobacterium microti ,Restriction fragment length polymorphism ,Mycobacterium africanum - Abstract
The successful use of DNA amplification for the detection of tuberculous mycobacteria crucially depends on the choice of the target sequence, which ideally should be present in all tuberculous mycobacteria and absent from all other bacteria. In the present study we developed a PCR procedure based on the intergenic region (IR) separating two genes encoding a recently identified mycobacterial two-component system named SenX3-RegX3. The senX3-regX3 IR is composed of a novel type of repetitive sequence, called mycobacterial interspersed repetitive units (MIRUs). In a survey of 116 Mycobacterium tuberculosis strains characterized by different IS 6110 restriction fragment length polymorphisms, 2 Mycobacterium africanum strains, 3 Mycobacterium bovis strains (including 2 BCG strains), and 1 Mycobacterium microti strain, a specific PCR fragment was amplified in all cases. This collection included M. tuberculosis strains that lack IS 6110 or mtp40 , two target sequences that have previously been used for the detection of M. tuberculosis . No PCR fragment was amplified when DNA from other organisms was used, giving a sensitivity of 100% and a specificity of 100% in the confidence limit of this study. The numbers of MIRUs were found to vary among strains, resulting in six different groups of strains on the basis of the size of the amplified PCR fragment. However, the vast majority of the strains (approximately 90%) fell within the same group, containing two 77-bp MIRUs followed by one 53-bp MIRU. more...
- Published
- 1998
- Full Text
- View/download PDF
11. Comparison of the Real-Time PCR Method and the Gen-Probe Amplified Mycobacterium tuberculosis Direct Test for Detection of Mycobacterium tuberculosis in Pulmonary and Nonpulmonary Specimens
- Author
-
Sylvie Armand, Odile Capilliez, Anne Vachée, Christine Dumoulin, René Courcol, and Nadine Lemaître
- Subjects
Microbiology (medical) ,Tuberculosis ,Biology ,Polymerase Chain Reaction ,Sensitivity and Specificity ,Microbiology ,law.invention ,Mycobacterium tuberculosis ,Tuberculosis diagnosis ,Direct test ,law ,medicine ,Humans ,Lung ,Tuberculosis, Pulmonary ,Polymerase chain reaction ,Respiratory disease ,Mycobacteriology and Aerobic Actinomycetes ,medicine.disease ,biology.organism_classification ,medicine.anatomical_structure ,Real-time polymerase chain reaction ,Organ Specificity - Abstract
Real-time PCR was compared to Amplified Mycobacterium tuberculosis Direct Test (AMTDII) for 100 clinical specimens. The overall sensitivities of the real-time PCR method and AMTDII were similar for respiratory and nonrespiratory specimens. However, real-time PCR seemed to be less susceptible to amplification inhibitors than AMTDII. more...
- Published
- 2004
- Full Text
- View/download PDF
12. First case of fatal bacteremia due to Nocardia neocaledoniensis
- Author
-
Alexandre Regueme, Anne Vachee, Claire Duployez, Anne-Emilie Petit, Pauline Coulon, Frédéric Wallet, and Caroline Loiez
- Subjects
Nocardia neocaledoniensis ,Bacteremia ,MALDI-TOF ,Infectious and parasitic diseases ,RC109-216 - Abstract
Nocardia neocaledoniensis is an uncommon cause of human-infections. Few cases are reported in the literature. We describe the first case of bacteremia caused by N. neocaledoniensis. This article underlines the importance of mass spectrometry for easy and rapid identification of such bacterium. more...
- Published
- 2020
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.